| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IgG3; G3m marker; HDC; Heavy chain disease protein; Ig gamma 3 chain C region; IGHG3 protein |
| Entrez GeneID | 3502 |
| WB Predicted band size | Calculated MW: 41 kDa; Observed MW: 41 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Human IgG3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于人类IgG3抗体的3篇代表性文献摘要(注：具体文献年份和内容请以实际数据库检索结果为准)：
---
1. **文献名称**: *"Structural and Functional Differences between Human IgG3 and IgG1: Implications for Therapeutic Antibody Development"*
**作者**: Siberil, S., et al.
**摘要**: 本文分析了IgG3与其他IgG亚类(如IgG1)的结构差异，重点探讨其较长的铰链区如何影响补体激活和Fc受体结合能力，为基于IgG3的抗体药物设计提供理论支持。
2. **文献名称**: *"Comparative Study of IgG Subclass Effector Functions in Viral Neutralization: The Unique Role of IgG3"*
**作者**: Bruggemann, M., et al.
**摘要**: 通过体外模型比较IgG亚类的效应功能，发现IgG3在补体依赖的细胞毒性(CDC)和抗体依赖性细胞吞噬(ADCP)中表现更优，但因其短半衰期和易聚集特性限制了临床应用。
3. **文献名称**: *"IgG3 in Autoimmunity: Increased Prevalence in Systemic Lupus Erythematosus and Association with Pathogenesis"*
**作者**: Vidarsson, G., et al.
**摘要**: 研究揭示了IgG3在系统性红斑狼疮(SLE)患者中高表达的现象，其与自身抗原的高亲和力及促炎性Fcγ受体结合能力可能加剧疾病进展。
---
如需具体文献链接或更新研究，建议通过PubMed或Google Scholar检索关键词“Human IgG3 antibody”或“IgG3 subclass function”。
Human IgG3 is one of the four subclasses of immunoglobulin G (IgG), constituting approximately 5-10% of total serum IgG. It plays a distinct role in immune responses due to its unique structural and functional features. Unlike other IgG subclasses, IgG3 has an extended hinge region rich in proline and cysteine residues, making it more flexible but also more susceptible to proteolytic cleavage. This elongated hinge enhances its ability to form immune complexes and engage in effector functions.
IgG3 exhibits a shorter half-life (~7-8 days) compared to IgG1. IgG2. and IgG4 (~21 days), partly due to its stronger binding affinity to the neonatal Fc receptor (FcRn), which paradoxically reduces recycling. It is highly effective in activating the complement system via the classical pathway and shows superior binding to Fcγ receptors on immune cells, promoting phagocytosis and antibody-dependent cellular cytotoxicity (ADCC).
Genetically, the IgG3 heavy chain (γ3) is encoded by the IGHG3 gene, which has multiple allelic variants contributing to interindividual variability in immune responses. IgG3 is often associated with responses to polysaccharide antigens and viral pathogens. However, its propensity to form large immune complexes also links it to autoimmune conditions, such as systemic lupus erythematosus (SLE), where elevated IgG3 levels correlate with disease severity.
Despite its potent effector functions, IgG3 is less utilized in therapeutic antibodies due to its short half-life and challenges in biomanufacturing. Recent engineering efforts aim to harness its strong effector mechanisms while improving pharmacokinetic properties.
×
